U.S. markets open in 5 hours 12 minutes

Misonix, Inc. (MSON)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.67+0.47 (+3.56%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close13.20
Bid0.00 x 800
Ask13.67 x 900
Day's Range13.09 - 13.76
52 Week Range6.71 - 23.31
Avg. Volume105,075
Market Cap237.334M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.88
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Misonix to Present at the 40th Annual Canaccord Genuity Growth Conference

    FARMINGDALE, N.Y., July 30, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 40th Annual Canaccord Genuity Growth Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Wednesday, August 12th at 10:30 a.m. ET. Management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the day on August 12th and 13th. If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at mson@jcir.com.About Misonix, Inc. Misonix, Inc. (Nasdaq: MSON) designs, manufactures and markets minimally invasive ultrasonic medical devices used for precise bone sculpting, removal of soft and hard tumors and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. The Company combined its SonicOne wound debridement application with its recently acquired TheraSkin product, a leading cellular skin substitute indicated for all wound treatments. The Company’s sales force operates as two divisions, Surgical (Neuro and Spine Applications) and Wound. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.Contact:    Joe Dwyer                                                                                                Chief Financial Officer                                                                                         Misonix, Inc.                                                                                             631-927-9113Norberto Aja, Jennifer Neuman JCIR 212-835-8500 or mson@jcir.com

  • What Percentage Of Misonix, Inc. (NASDAQ:MSON) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Misonix, Inc. (NASDAQ:MSON) Shares Do Insiders Own?

    If you want to know who really controls Misonix, Inc. (NASDAQ:MSON), then you'll have to look at the makeup of its...

  • GlobeNewswire

    Misonix Reports Preliminary Fiscal 2020 Fourth Quarter Revenue of Approximately $13.5 Million

    Full Year Revenue of Approximately $62.3 Million Company Focus on Shareholder Value Creation, Cash Preservation, Expense Reduction, Workforce Efficiency and Operational.